CA3056819A1 - Methods and compositions for stimulating immune response - Google Patents
Methods and compositions for stimulating immune response Download PDFInfo
- Publication number
- CA3056819A1 CA3056819A1 CA3056819A CA3056819A CA3056819A1 CA 3056819 A1 CA3056819 A1 CA 3056819A1 CA 3056819 A CA3056819 A CA 3056819A CA 3056819 A CA3056819 A CA 3056819A CA 3056819 A1 CA3056819 A1 CA 3056819A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- rna molecule
- antigen
- variant
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017057094 | 2017-03-24 | ||
| EPPCT/EP2017/057094 | 2017-03-24 | ||
| PCT/EP2018/057206 WO2018172426A1 (en) | 2017-03-24 | 2018-03-21 | Methods and compositions for stimulating immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3056819A1 true CA3056819A1 (en) | 2018-09-27 |
Family
ID=61911533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3056819A Pending CA3056819A1 (en) | 2017-03-24 | 2018-03-21 | Methods and compositions for stimulating immune response |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11471522B2 (https=) |
| EP (2) | EP3600389B1 (https=) |
| JP (3) | JP7651261B2 (https=) |
| AU (1) | AU2018240421B2 (https=) |
| CA (1) | CA3056819A1 (https=) |
| ES (1) | ES2951684T3 (https=) |
| WO (1) | WO2018172426A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2951684T3 (es) | 2017-03-24 | 2023-10-24 | BioNTech SE | Métodos y composiciones para estimular la respuesta inmune |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| FI20215508A1 (en) | 2020-04-09 | 2021-10-10 | Niemelae Erik Johan | Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection |
| WO2022099003A1 (en) * | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| CN114733455B (zh) * | 2022-04-15 | 2023-02-14 | 北京田园奥瑞生物科技有限公司 | 一种利用生物改性β-环糊精纳米磁颗粒进行快速哺乳动物精子分型的方法 |
| WO2025144938A1 (en) | 2023-12-26 | 2025-07-03 | Emmune, Inc. | Systems for nucleic acid transfer |
| WO2025223684A1 (en) | 2024-04-23 | 2025-10-30 | BioNTech SE | Methods and compositions for stimulating immune response |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007526253A (ja) * | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 免疫刺激性ウイルスｒｎａオリゴヌクレオチド |
| EP2167662A2 (en) * | 2007-05-14 | 2010-03-31 | Technische Universität München | Pharmaceutical compounds comprising abasic oligonucleotides |
| EP3263707A1 (en) * | 2009-03-17 | 2018-01-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Tlr8 ligand and uses thereof |
| US8840902B2 (en) * | 2010-03-16 | 2014-09-23 | Biontech Ag | Tumor vaccination involving a humoral immune response against self-proteins |
| WO2013126963A1 (en) * | 2012-02-29 | 2013-09-06 | Benitec Biopharma Limited | Pain treatment |
| WO2016179034A2 (en) | 2015-05-01 | 2016-11-10 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs |
| JP7384512B2 (ja) | 2015-10-22 | 2023-11-21 | モデルナティエックス インコーポレイテッド | 広域インフルエンザウイルスワクチン |
| ES2951684T3 (es) | 2017-03-24 | 2023-10-24 | BioNTech SE | Métodos y composiciones para estimular la respuesta inmune |
-
2018
- 2018-03-21 ES ES18716138T patent/ES2951684T3/es active Active
- 2018-03-21 EP EP18716138.5A patent/EP3600389B1/en active Active
- 2018-03-21 WO PCT/EP2018/057206 patent/WO2018172426A1/en not_active Ceased
- 2018-03-21 CA CA3056819A patent/CA3056819A1/en active Pending
- 2018-03-21 AU AU2018240421A patent/AU2018240421B2/en active Active
- 2018-03-21 US US16/496,858 patent/US11471522B2/en active Active
- 2018-03-21 EP EP23172071.5A patent/EP4241786A3/en active Pending
- 2018-03-21 JP JP2019551991A patent/JP7651261B2/ja active Active
-
2022
- 2022-09-12 US US17/931,215 patent/US12168051B2/en active Active
- 2022-12-02 JP JP2022193597A patent/JP2023036615A/ja active Pending
-
2024
- 2024-10-11 JP JP2024178540A patent/JP2025023916A/ja active Pending
- 2024-11-13 US US18/946,351 patent/US20260115272A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020511504A (ja) | 2020-04-16 |
| EP4241786A2 (en) | 2023-09-13 |
| JP2025023916A (ja) | 2025-02-19 |
| JP2023036615A (ja) | 2023-03-14 |
| EP3600389A1 (en) | 2020-02-05 |
| EP4241786A3 (en) | 2023-12-27 |
| JP7651261B2 (ja) | 2025-03-26 |
| EP3600389B1 (en) | 2023-05-10 |
| US11471522B2 (en) | 2022-10-18 |
| US20260115272A1 (en) | 2026-04-30 |
| ES2951684T3 (es) | 2023-10-24 |
| US20200197508A1 (en) | 2020-06-25 |
| US20230074462A1 (en) | 2023-03-09 |
| AU2018240421B2 (en) | 2025-03-06 |
| AU2018240421A1 (en) | 2019-09-26 |
| WO2018172426A1 (en) | 2018-09-27 |
| US12168051B2 (en) | 2024-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12186275B2 (en) | Enhancing the effect of CAR-engineered T cells by means of nucleic acid vaccination | |
| US12168051B2 (en) | Methods and compositions for stimulating immune response | |
| US20230119334A1 (en) | Antigen receptors and uses thereof | |
| US11702631B2 (en) | Antigen receptors and uses thereof | |
| HK40103250A (en) | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination | |
| HK40072989A (en) | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination | |
| HK1250330B (en) | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination | |
| HK1247098B (en) | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230315 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240716 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240916 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241223 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: N-6-6-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250109 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: N-6-6-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250211 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250211 Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250812 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250812 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260106 |